152 related articles for article (PubMed ID: 34843261)
1. Annotating BCMA Expression in Multiple Myelomas.
Wei W; Zhang Y; Zhang D; Liu Q; An S; Chen Y; Huang G; Liu J
Mol Pharm; 2022 Oct; 19(10):3492-3501. PubMed ID: 34843261
[TBL] [Abstract][Full Text] [Related]
2. ImmunoPET imaging of multiple myeloma with [
Wang C; Chen Y; Hou YN; Liu Q; Zhang D; Zhao H; Zhang Y; An S; Li L; Hou J; Huang G; Liu J; Zhao YJ; Wei W
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2749-2760. PubMed ID: 33543326
[TBL] [Abstract][Full Text] [Related]
3. ImmunoPET imaging of human CD8
Zhao H; Wang C; Yang Y; Sun Y; Wei W; Wang C; Wan L; Zhu C; Li L; Huang G; Liu J
J Nanobiotechnology; 2021 Feb; 19(1):42. PubMed ID: 33563286
[TBL] [Abstract][Full Text] [Related]
4. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
An S; Zhang D; Zhang Y; Wang C; Shi L; Wei W; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2682-2692. PubMed ID: 35147737
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.
Huang W; Liang C; Zhang Y; Zhang D; An S; Wu Q; Li J; Zhao H; Wang C; Cui J; Bao Z; Huang G; Wei W; Liu J
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):380-394. PubMed ID: 37792026
[TBL] [Abstract][Full Text] [Related]
6. Development and comparison of
Wei W; Zhang D; Zhang Y; Li L; Jin Y; An S; Lv C; Zhao H; Wang C; Huang Y; Dong J; Huang G; Liu J
Mol Ther Oncolytics; 2022 Dec; 27():305-314. PubMed ID: 36570796
[TBL] [Abstract][Full Text] [Related]
7. ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers.
Liang C; Huang W; Zhang Y; Zhang D; An S; Wu Q; Zhao H; Wang C; Huang G; Wei W; Liu J
Mol Pharm; 2023 Aug; 20(8):4184-4195. PubMed ID: 37403817
[TBL] [Abstract][Full Text] [Related]
8. Annotating CD38 Expression in Multiple Myeloma with [
Wei W; Zhang D; Wang C; Zhang Y; An S; Chen Y; Huang G; Liu J
Mol Pharm; 2022 Oct; 19(10):3502-3510. PubMed ID: 34846151
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
10. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
Brand C; Longo VA; Groaning M; Weber WA; Reiner T
Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
[TBL] [Abstract][Full Text] [Related]
11.
Suman SK; Mukherjee A; Pandey U; Chakraborty A; Rakshit S; Tawate M; Sarma HD
Cancer Biother Radiopharm; 2023 Feb; 38(1):38-50. PubMed ID: 36413344
[No Abstract] [Full Text] [Related]
12. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
13. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
14. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of CD54-targeted immunoPET imaging in solid tumors.
Wei W; Jiang D; Lee HJ; Li M; Kutyreff CJ; Engle JW; Liu J; Cai W
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2765-2775. PubMed ID: 32279097
[TBL] [Abstract][Full Text] [Related]
16. A Gallium-67/68-Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake.
Uehara T; Yokoyama M; Suzuki H; Hanaoka H; Arano Y
Clin Cancer Res; 2018 Jul; 24(14):3309-3316. PubMed ID: 29666303
[No Abstract] [Full Text] [Related]
17. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
18. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
19. Clinical Translation of [
Xavier C; Blykers A; Laoui D; Bolli E; Vaneyken I; Bridoux J; Baudhuin H; Raes G; Everaert H; Movahedi K; Van Ginderachter JA; Devoogdt N; Caveliers V; Lahoutte T; Keyaerts M
Mol Imaging Biol; 2019 Oct; 21(5):898-906. PubMed ID: 30671739
[TBL] [Abstract][Full Text] [Related]
20. Targeting of MMP2 activity in malignant tumors with a 68Ga-labeled gelatinase inhibitor cyclic peptide.
Liu Q; Pan D; Cheng C; Zhang A; Ma C; Wang L; Zhang D; Liu H; Jiang H; Wang T; Xu Y; Yang R; Chen F; Yang M; Zuo C
Nucl Med Biol; 2015 Dec; 42(12):939-44. PubMed ID: 26344861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
